The impact of new data in the treatment of advanced hepatocellular carcinoma Journal Article
| Authors: | Abou-Alfa, G. K.; Venook, A. P. |
| Article Title: | The impact of new data in the treatment of advanced hepatocellular carcinoma |
| Abstract: | Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, causing 500,000 deaths yearly. The risk factors mostly responsible for the rising incidence of HCC in the Western hemisphere are hepatitis C, alcoholic cirrhosis, and nonalcoholic steatohepatitis, which most commonly leads to HCC in the setting of cirrhosis. Over the past 30 years, several chemotherapeutic single agents and combinations have been tested in HCC, yet none have demonstrated any improvement in survival. Recently, the multitargeted anti-angiogenic and Raf kinase inhibitor sorafenib has shown a survival advantage as a single agent and improved outcomes in combination with doxorubicin. Other novel agents have also shown intriguing outcomes as single agents (sunitinib) or in combination (bevacizumab and erlotinib). The encouraging results and clinical information gathered in recent trials are generating important clinical questions regarding which patients to treat, how to accommodate concurrent cirrhosis, and which parameters to use to monitor efficacy and the potential benefit from therapy. © Current Medicine Group LLC 2008. |
| Keywords: | cancer chemotherapy; cancer survival; overall survival; clinical trial; fatigue; neutropenia; review; sorafenib; bevacizumab; cisplatin; doxorubicin; erlotinib; fluorouracil; interferon; placebo; sunitinib; diarrhea; drug withdrawal; gastrointestinal hemorrhage; hepatitis c; hypertension; liver cell carcinoma; monotherapy; side effect; antineoplastic agents; carcinoma, hepatocellular; clinical trials as topic; liver neoplasms; capecitabine; gemcitabine; cancer staging; antineoplastic agent; cancer incidence; metabolism; progression free survival; controlled clinical trial; bone marrow suppression; leukopenia; randomized controlled trial; peripheral neuropathy; epidermal growth factor receptor; combination chemotherapy; receptor, epidermal growth factor; aminotransferase blood level; drug antagonism; karnofsky performance status; cardiotoxicity; stomach ulcer; liver tumor; scoring system; transient ischemic attack; sepsis; oxaliplatin; hand foot syndrome; digestive system perforation; lapatinib; epidermal growth factor receptor kinase inhibitor; chinese university prognostic index; nonalcoholic fatty liver; esophagus hemorrhage; nolatrexed; alcohol liver cirrhosis; cancer of the liver italian program score; child pugh scoring system; gretch scoring system; heart left ventricular dysfunction |
| Journal Title: | Current Oncology Reports |
| Volume: | 10 |
| Issue: | 3 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2008-05-01 |
| Start Page: | 199 |
| End Page: | 205 |
| Language: | English |
| DOI: | 10.1007/s11912-008-0031-x |
| PUBMED: | 18765149 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 10" - "Export Date: 17 November 2011" - "CODEN: CORUA" - "Source: Scopus" |
